According to Nova One Advisor, the global viral vector & plasmid DNA manufacturing size is calculated at USD 7.54 billion in 2025 and is expected to surpass around USD 27.71 billion by 2034, growing ...

(MENAFN- GlobeNewsWire - Nasdaq) According to Nova One Advisor, the global viral vector & plasmid DNA manufacturing size is calculated at USD 7.54 billion in 2025 and is expected to surpass around USD ...

MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...

Molecular cloning relies on two key components to construct recombinant DNA: 1) a DNA vector and 2) one or more DNA fragments containing the gene(s) of interest (GOI). To produce a GOI fragment, DNA ...

On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics' latest advancement in the ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced Dyno-bn8, a novel adeno-associated virus ...

Bharat Biotech expands into advanced biologics with Nucelion Therapeutics, a new CRDMO for cell and gene therapy manufacturing, positioning India as a rising hub for global biotherapeutics.

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc ...

Bharat Biotech is venturing into advanced therapies by launching Nucelion Therapeutics, a subsidiary focused on cell and gene therapies. This new entity will offer comprehensive development and ...

Throughout the forecast period, the report presents detailed estimates regarding market share, overall market size, and industry growth rates. It also offers an in-depth overview of the competitive ...